CA
ANRO icon

Clearstead Advisors’s Alto Neuroscience ANRO Stock Holding History

Clearstead Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,312
Closed -$299K – 3738
2026
Q1 		$299K Buy
+13,312
New +$247K ﹤0.01% 863
2025
Q3 		– Sell
-178
Closed -$392 – 3272
2025
Q2 		$392 Buy
+178
New +$424 ﹤0.01% 2514

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Clearstead Advisors's ANRO Position: Q2 2026 in Review

Clearstead Advisors sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 13,312 shares — an estimated $299K sold.

Clearstead Advisors first reported a position in ANRO in Q2 2025 and held it in 2 quarters. The position peaked at $299K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Clearstead Advisors reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
  • Clearstead Advisors sold 13,312 Alto Neuroscience shares in Q2 2026, an estimated $299K.
  • Clearstead Advisors first reported a position in Alto Neuroscience in Q2 2025 and held it in 2 quarters.
  • Clearstead Advisors's Alto Neuroscience position peaked at $299K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.